Pharmacopeia Changes Name to Accelrys and Appoints Mark Emkjer New Chief Executive Officer
Pharmacopeia Inc. announced that on May 11, 2004, its stockholders approved changing the company’s name to Accelrys Inc. The new name is part of a corporate restructuring that included the spin-off of the company’s drug discovery business, Pharmacopeia Drug Discovery Inc. Accelrys is now a company solely focused on delivering scientific software solutions to the life sciences and materials research industries.
In connection with the spin-off, the company announced today that its board of directors has appointed Mark Emkjer, previously the Accelrys president, to serve as president and chief executive officer of the company. Mr. Emkjer has been president of Accelrys since December 2002, having previously served as president and chief operating officer of Sunquest Information Systems Inc. and as president and chief executive officer of Pace Health Management Systems Inc.
Mark Emkjer was also elected to the Accelrys board of directors on May 11, 2004. Other members of the Accelrys board of directors are Kenneth Coleman, chairman and CEO of ITM Software Corp., Gary Costley, Ph.D., chairman and CEO of International Multifoods Corp. and Ricardo Levy, Ph.D. and chairman of the board of Catalytica Energy Systems. In connection with the spin-off, Joseph Mollica, Ph.D. resigned from his officer and Board positions with Accelrys, and Frank Baldino, Jr., Ph.D., James Marino and Paul Bartlett, Ph.D. each resigned from their respective Accelrys board positions. Dr.Mollica, Dr. Baldino, Mr. Marino and Dr. Bartlett will all serve on the board of Pharmacopeia Drug Discovery.
About Accelrys
Accelrys Inc. is the parent of Accelrys Software Solutions Inc., a leading provider of software for computation, simulation and the management and mining of scientific data used by biologists, chemists and materials scientists for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today’s leading research organizations. The company is headquartered in San Diego. For more information about Accelrys, visit its Web site at www.accelrys.com .
When used anywhere in this document, the words “expects”, “believes”, “anticipates”, “estimates”, and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Accelrys. Accelrys has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Accelrys’ strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions and other risks described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and subsequent reports on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
